WH-4-023

CAS No. 837422-57-8

WH-4-023( WH-4-023 | WH4-023 | WH 4-023 | WH-4023 )

Catalog No. M16103 CAS No. 837422-57-8

WH-4-023 is a potent and orally active Lck/Src inhibitor with IC50 of 2 nM and 6 nM in cell-free assays, respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 42 In Stock
5MG 61 In Stock
10MG 91 In Stock
25MG 149 In Stock
50MG 186 In Stock
100MG 332 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    WH-4-023
  • Note
    Research use only, not for human use.
  • Brief Description
    WH-4-023 is a potent and orally active Lck/Src inhibitor with IC50 of 2 nM and 6 nM in cell-free assays, respectively.
  • Description
    WH-4-023 is a potent and orally active Lck/Src inhibitor with IC50 of 2 nM and 6 nM in cell-free assays, respectively.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    WH-4-023 | WH4-023 | WH 4-023 | WH-4023
  • Pathway
    Tyrosine Kinase
  • Target
    Src
  • Recptor
    Lck| Src
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    837422-57-8
  • Formula Weight
    568.67
  • Molecular Formula
    C32H36N6O4
  • Purity
    >98% (HPLC)
  • Solubility
    Ethanol: 6 mg/mL warmed (10.55 mM); DMSO: 12 mg/mL warmed (21.1 mM)
  • SMILES
    O=C(OC1=C(C)C=CC=C1C)N(C2=CC=C(OC)C=C2OC)C3=NC(NC4=CC=C(N5CCN(C)CC5)C=C4)=NC=C3
  • Chemical Name
    2,6-dimethylphenyl (2,4-dimethoxyphenyl)(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)carbamate

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Martin MW, et al. J Med Chem. 2006 Aug 10;49(16): 4981-9
molnova catalog
related products
  • PP 3

    PP 3 is a Negative control for the Src kinase inhibitor PP 2.

  • RK-24466

    RK-24466 is a selective and potent inhibitor of Lck, inhibits Lck (64-509) and LckCD isoforms with IC50s of less than 1 and 2 nM, respectively.

  • KX2-391

    KX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.